睡眠外科门诊患者中GLP-1受体激动剂的使用情况
本研究回顾性分析了384例睡眠外科门诊OSA患者,64.8%符合FDA GLP-1 RA用药标准,其中28.1%正在使用。使用率高于一般人群,Medicaid保险与使用率较低相关,BMI≥30与使用率较高相关。
要点
- 睡眠外科门诊OSA患者中约三分之二符合GLP-1 RA用药标准。
- 符合标准者中28.1%正在使用GLP-1 RA,以司美格鲁肽和替尔泊肽为主。
- Medicaid保险与使用率较低相关,BMI≥30与使用率较高相关。
核心结论
- 睡眠外科门诊OSA患者中大部分符合GLP-1 RA用药标准,使用率高于一般人群。
主要发现
- 队列平均年龄53.3±14.8岁,平均BMI 29.4±5.7 kg/m²,平均AHI 28.7±24.2事件/小时。
- 52.1%的患者曾尝试CPAP治疗。
- 384例中249例(64.8%)符合FDA GLP-1 RA用药标准,其中70例(28.1%)正在使用GLP-1 RA。
- 最常处方药物为司美格鲁肽(54.8%)和替尔泊肽(27.4%)。
- 停药或换药最常见原因为保险相关问题及不良反应。
关键数值与推荐
- GLP-1 RA符合标准依据FDA药品标签:糖尿病、肥胖或BMI≥27 kg/m²合并体重相关合并症。
临床怎么用
- 睡眠外科门诊应评估OSA患者GLP-1 RA用药资格,关注保险类型对用药可及性的影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are approved to treat obstructive sleep apnea (OSA), yet their use in an OSA population has not been characterized. This study evaluates GLP-1 RA use in patients presenting to a sleep surgery clinic. STUDY DESIGN: Retrospective. SETTING: Tertiary care institution. METHODS: Patients with OSA who presented to our sleep surgery clinic between October 2023 and March 2025 with available sleep studies were included (n = 384). Demographic data, body mass index (BMI), apnea-hypopnea index (AHI), OSA history, GLP-1 RA prescription data, and usage details were collected through chart review. Eligibility for GLP-1 RA was defined by FDA drug labeling criteria, with diabetes, obesity, or BMI ≥ 27 kg/m² with a weight-related comorbidity. RESULTS: The cohort had mean age 53.3 ± 14.8 years, BMI 29.4 ± 5.7 kg/m2, and AHI 28.7 ± 24.2 events/h. Most patients (52.1%) had tried CPAP. Among the full cohort (n = 384), 249 patients (64.8%) met FDA-approved drug labeling criteria for GLP-1 RA use, and there were 70 (28.1%) current GLP-1 RA users among eligible patients. Semaglutide (54.8%) and tirzepatide (27.4%) were the most prescribed. The most common reasons for discontinuing or changing GLP-1 RA types were insurance-related issues and adverse effects. Among eligible patients, having Medicaid was associated with lower likelihood of using GLP-1 RAs (adjusted odds ratio 0.25, P = .04) while BMI ≥30 kg/m2 (adjusted odds ratio 3.45, P < .001) was associated with higher likelihood. CONCLUSION: Among sleep surgery clinic patients, a large proportion were eligible for GLP-1 RA use, and utilization was high compared to that of the general population.
引用
- Kutler RB, Lin A, Zhang L, et al. Glucagon-Like Peptide-1 Receptor Agonist Utilization Among Sleep Surgery Clinic Patients. Otolaryngol Head Neck Surg. 2026. PMID: 41979383. doi:10.1002/ohn.70231
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。